ReviewJournal of cellular and molecular medicine2010
Injectable cardiac tissue engineering for the treatment of myocardial infarction.
Review in Journal of cellular and molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Injectable hydrogel-based combination therapy for myocardial infarction: a systematic review and Meta-analysis of preclinical trials.BMC cardiovascular disorders · 2024Pooled it
- Controlled Delivery of Gasotransmitters for Cardiovascular Therapy: Molecular Mechanisms, Engineered Platforms, and Translational Perspectives.International journal of nanomedicine · 2026Review
- Toward strategies to advance the conductive properties of hydrogel formulations for cardiac tissue engineering.iScience · 2025Review
- Cardiovascular Ischemia: Advancement and Potential Use of Collagen-Based Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Hydrogel encapsulating gold nanoparticles for targeted delivery of nitroglycerin to reduce post-cardiac dysfunction inflammation by inhibiting the Wnt/β-catenin signaling pathway.Inflammopharmacology · 2024Article
- Review
- Advances in the design, generation, and application of tissue-engineered myocardial equivalents.Frontiers in bioengineering and biotechnology · 2023Review
- Characterization of decellularized left and right ventricular myocardial matrix hydrogels and their effects on cardiac progenitor cells.Journal of molecular and cellular cardiology · 2022Article
- Development of an Injectable Shear-Thinning Nanocomposite Hydrogel for Cardiac Tissue Engineering.Gels (Basel, Switzerland) · 2022Article
- Biomaterials-based Approaches for Cardiac Regeneration.Korean circulation journal · 2021Review
- Constructing a cell microenvironment with biomaterial scaffolds for stem cell therapy.Stem cell research & therapy · 2021Review
- Extracellular matrix-based biomaterials for cardiac regeneration and repair.Heart failure reviews · 2021Review
- Controlling Structure with Injectable Biomaterials to Better Mimic Tissue Heterogeneity and Anisotropy.Advanced healthcare materials · 2021Review
- Accounting for Material Changes in Decellularized Tissue with Underutilized Methodologies.BioMed research international · 2021Review
- Optimizing Anisotropic Polyurethane Scaffolds to Mechanically Match with Native Myocardium.ACS biomaterials science & engineering · 2020Article
- Collagen biomaterial for the treatment of myocardial infarction: an update on cardiac tissue engineering and myocardial regeneration.Drug delivery and translational research · 2019Review
- Nanotechnology and multipotent adult progenitor cells in Reparative Medicine: therapeutic perspectives.Einstein (Sao Paulo, Brazil) · 2018Review
- Injectable Hydrogels for Cardiac Tissue Engineering.Macromolecular bioscience · 2018Review
- Gentamicin-Loaded Polysaccharide Membranes for Prevention and Treatment of Post-operative Wound Infections in the Skeletal System.Pharmaceutical research · 2017Article
- Injectable Hydrogels for Cardiac Tissue Repair after Myocardial Infarction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Future perspectives Heart disease is a leading cause of morbidity and mortality worldwide. Myocardial infarction leads to permanent loss of cardiac tissue and ultimately heart failure. However, current therapies could only stall the progression of the disease. Thus, new therapies are needed to regenerate damaged hearts to overcome poor prognosis of patients with heart failure. The shortage of heart donors is also a factor for innovating new therapies. Although the cardiac performance by cell-based therapy has improved, unsatisfactory cell retention and transplant survival still plague this technique. Because biomaterials can improve the cell retention, survival and differentiation, cardiac tissue engineering is now being explored as an approach to support cell-based therapies and enhance their efficacy for cardiac disease. In the last decade, cardiac tissue engineering has made considerable progress. Among different kinds of approaches in the cardiac tissue engineering, the approach of injectable cardiac tissue engineering is more minimally invasive than that of in vitro engineered tissue or epicardial patch implantation. It is therefore clinically appealing. In this review, we strive to describe the major progress in the filed of injectable cardiac tissue engineering, including seeding cell sources, biomaterials and novel findings in preclinical studies and clinical applications. The remaining problems will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.